| Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States JA Roth, SD Sullivan, VW Lin, A Bansal, AG Purdum, L Navale, P Cheng, ... Journal of medical economics 21 (12), 1238-1245, 2018 | 112 | 2018 |
| Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL … MC Pasquini, FL Locke, AF Herrera, T Siddiqi, A Ghobadi, KV Komanduri, ... Blood 134, 764, 2019 | 93 | 2019 |
| Cost-effectiveness of cetuximab as first-line treatment for metastatic colorectal cancer in the United States V Shankaran, JD Ortendahl, AG Purdum, B Bolinder, AM Anene, GH Sun, ... American Journal of Clinical Oncology 41 (1), 65-72, 2018 | 35 | 2018 |
| Direct costs associated with relapsed diffuse large B‐cell lymphoma therapies A Purdum, R Tieu, SR Reddy, MS Broder The oncologist 24 (9), 1229-1236, 2019 | 34 | 2019 |
| Medicare patients receiving chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma: a first real-world look at patient characteristics, healthcare utilization and costs KM Kilgore, I Mohammadi, A Schroeder, C Teigland, A Purdum, GL Shah Blood 134, 793, 2019 | 32 | 2019 |
| Comparing total health care costs and treatment patterns of HIV patients in a managed care setting AG Purdum, KA Johnson, DR Globe AIDS care 16 (6), 767-780, 2004 | 23 | 2004 |
| Estimating long-term survival for patients with relapsed or refractory large B-cell lymphoma treated with chimeric antigen receptor therapy: a comparison of standard and … A Bansal, SD Sullivan, VW Lin, AG Purdum, L Navale, P Cheng, ... Medical Decision Making 39 (3), 294-298, 2019 | 20 | 2019 |
| Systematic literature review of health-related quality of life among aggressive non-Hodgkin lymphoma survivors VW Lin, B Blaylock, J Epstein, A Purdum Current Medical Research and Opinion 34 (8), 1529-1535, 2018 | 12 | 2018 |
| Health utilities for patients with relapsed or refractory large B-cell lymphoma (R/R-LBCL): ad hoc analysis from an axicabtagene ciloleucel (Axi-cel) safety management study VW Lin, Y Jiang, LH Chuang, L Navale, P Cheng, A Purdum Bone Marrow Transplantation 53, 879-879, 2018 | 11 | 2018 |
| Real-world management and outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma treated in the United States AJ Klink, C Nabhan, CH Lee, J Laney, Y Yang, AG Purdum J Clin Pathways 6 (1), 44-53, 2020 | 10 | 2020 |
| Overall survival (OS) and transplantation (ASCT) utilization in real-world patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL). C Nabhan, A Klink, CH Lee, JR Laney, Y Yang, AG Purdum Journal of Clinical Oncology 36 (15_suppl), 7545-7545, 2018 | 8 | 2018 |
| Cost-effectiveness of cetuximab as first-line treatment for metastatic colorectal cancer in the United States JD Ortendahl, TG Bentley, AM Anene, AG Purdum, B Bolinder Value in Health 17 (3), A86, 2014 | 5 | 2014 |
| The first retrospective commercial claims-based analysis of CAR T treated patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) A Purdum, J Johnson, A Bonagura, L Nyamutswa, C Elliott, LS Lal Blood 136, 31, 2020 | 3 | 2020 |
| Medicare patients receiving chimeric antigen receptor T-cell therapy for non-hodgkin lymphoma: a real-world look at patient characteristics, healthcare utilization and costs KM Kilgore, I Mohammadi, A Schroeder, C Teigland, AG Purdum, ... Biology of Blood and Marrow Transplantation 26 (3), S43-S44, 2020 | 3 | 2020 |
| CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion M Boeri, AG Purdum, J Sutphin, B Hauber, JA Kaye Future Oncology 17 (34), 4697-4709, 2021 | 2 | 2021 |
| Real world survival rates and healthcare utilization among SEER-Medicare patients treated with hematopoietic stem cell transplant (HSCT) for relapsed/refractory diffuse large b … AG Purdum, T Niecko, Y Yang Journal of Clinical Oncology 36 (15_suppl), e19502-e19502, 2018 | 2 | 2018 |
| Cost and Healthcare Utilization in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Analysis of Medicare Beneficiaries Receiving Chimeric Antigen Receptor T-Cell … GL Shah, I Mohammadi, AG Purdum, AC Wong, A Schroeder, KM Kilgore 2021 TCT| Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, 2021 | 1 | 2021 |
| Cost and Healthcare Utilization in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Analysis of Medicare Beneficiaries Receiving Chimeric Antigen Receptor T-Cell … I Mohammadi, AG Purdum, AC Wong, A Schroeder, KM Kilgore, GL Shah Blood 136, 4, 2020 | 1 | 2020 |
| Estimating long-term survival for patients with relapsed or refractory aggressive non-Hodgkin lymphoma treated with anti-CD19 chimeric antigen receptor T-Cell therapy: A … A Bansal, V Lin, SD Sullivan, L Navale, JA Roth, AG Purdum, SD Ramsey Biology of Blood and Marrow Transplantation 24 (3), S310, 2018 | 1 | 2018 |
| Total 1-year cost of diffuse large B-cell lymphoma (DLBCL) beyond first line (1L) therapy: A retrospective cohort analysis. A Purdum, R Tieu, SR Reddy, M Broder Journal of Clinical Oncology 35 (15_suppl), e18333-e18333, 2017 | 1 | 2017 |
